US PTAB IP Litigation
5,620 annotated decisions
Page 232 of 235 · 5,620 total
patent instituted · Jan 26, 2024
Cisco Systems, Inc. v.Portsmouth Network Corporation
· IPR2024-00503
Cisco Systems successfully navigated a discretionary denial challenge at the PTAB, leading to the institution of an IPR against Portsmouth Network Corp. over network resource allocation claims. The Board found that Cisco demonstrated a reasonable likelihood of prevailing on at least one claim, despite arguments regarding prior art redundancy and pending district court litigation.
patent all challenged claims upheld · Jan 26, 2024
Visa, Inc. v.Cortex MCP, Inc.
· IPR2024-00490
Visa's challenge to Cortex MCP's patent was upheld by the PTAB Director Review Panel. The panel affirmed the Board's finding that the prior art (Oborne) discloses the claimed credential verification limitation.
patent instituted · Jan 26, 2024
Visa, Inc. v.Cortex MCP, Inc.
· IPR2024-00488
The PTAB institution decision found that Visa, Inc.'s claims were likely obvious over prior art references including Oborne and Neafsey. The Board adopted Petitioner's claim constructions for key terms like 'scan,' leading to the institution of 17 claims under Section 103.
patent instituted · Jan 26, 2024
Arm Ltd. v.ICPillar LLC
· IPR2024-00476
Arm Ltd.'s IPR challenge against ICPillar LLC's '8924899 patent was instituted by the PTAB, focusing on obviousness over prior art including Rompaey and Banerjee. The Board adopted a broad claim construction for key software commands, allowing the case to proceed to trial.
patent instituted · Jan 26, 2024
VIVITRO LABS INC. v.BIOMEDICAL DEVICE CONSULTANTS & LABORATORIES OF COLORADO, LLC
· IPR2024-00320
VIVITRO LABS INC. successfully achieved institution at the PTAB for its IPR against Patent No. 9237935, challenging claims related to prosthetic heart valve testing systems. The Board found a reasonable likelihood of success over Dynatek regarding certain limitations, despite preliminary rejections on other grounds.
patent final · Jan 26, 2024
Cisco Systems, Inc. v.Portsmouth Network Corporation
· IPR2024-00503
The PTAB issued a Final Written Decision finding that claims 1-18 of the patent were unpatentable on grounds of obviousness over Kovvali and Kalman. The Board rejected the Petitioner's arguments, agreeing with the Patent Owner that there was no valid motivation to combine the references for resource allocation in ring topology data flow.
patent final · Jan 26, 2024
Visa, Inc. v.Cortex MCP, Inc.
· IPR2024-00490
The PTAB found numerous claims of U.S. Patent No. 11329973 unpatentable based on obviousness (103). The Board determined that the prior art, particularly Oborne, discloses key limitations related to token generation and issuing agency verification in digital credential systems. Claims 1, 3–8, and 10–16 were found invalid, while claims 2, 9, and 17 survived.
patent final · Jan 26, 2024
Visa, Inc. v.Cortex MCP, Inc.
· IPR2024-00488
The PTAB Board upheld the validity of Cortex MCP's claims (1-17) related to electronic credentials and tokenization. The Board rejected arguments that the claimed features were obvious over prior art references like Oborne, Neafsey, and Stafford.
patent terminated or settled · Jan 25, 2024
JACS Solutions, Inc. v.Global Tel*Link Corporation d/b/a ViaPath Technologies
· IPR2024-00484
JACS Solutions and Global Tel*Link jointly moved to terminate IPR2024-00484 after reaching a settlement. The Board authorized the termination, ending the review of patent 9,030,292.
patent terminated or settled · Jan 25, 2024
JACS Solutions, Inc. v.Global Tel*Link Corporation d/b/a ViaPath Technologies
· IPR2024-00484
JACS Solutions and Global Tel*Link settled their IPR dispute before the Board could institute a trial. The Board granted the joint motion to terminate and kept the settlement confidential.
patent · Jan 25, 2024
Visa, Inc. v.Cortex MCP, Inc.
· IPR2024-00486
Visa submits an authorized response urging the PTAB to deny Cortex MCP’s Director Review request, asserting that the request raises new, unraised arguments about the timing of verification in the Oborne prior art. Visa maintains that the Board’s obviousness finding is well‑supported and procedurally sound.
patent · Jan 25, 2024
Visa, Inc. v.Cortex MCP, Inc.
· IPR2024-00486
Cortex MCP seeks Director Review of the PTAB’s Final Written Decision that cancelled 29 claims of its token‑payment patent. The owner contends the Board invented a new obviousness theory not raised in Visa’s petitions, violating procedural rules.
patent null · Jan 25, 2024
TESLA, INC. v.iQar Inc.
· IPR2024-00499
Tesla, Inc. has filed a Petition challenging 17 claims of iQar Inc.'s patent (US 10,829,002) in the PTAB. The challenge asserts that the claims are obvious over various combinations of prior art references, including Kudo-325 and Kudo-066.
patent null · Jan 25, 2024
JACS Solutions, Inc. v.Global Tel*Link Corporation d/b/a ViaPath Technologies
· IPR2024-00484
JACS Solutions challenges Global Tel*Link's '9030292 Patent, asserting that 29 claims are obvious under 35 U.S.C. § 103. The petitioner argues that the claimed features of secure facility monitoring systems are predictable combinations of existing prior art in telecommunications and security technology.
patent instituted · Jan 25, 2024
TESLA, INC. v.iQar Inc.
· IPR2024-00499
Tesla successfully secured the institution of Inter Partes Review against iQar Inc.'s patent 10,829,002, challenging claims related to vehicle destination prediction and power management.
patent instituted · Jan 25, 2024
Visa, Inc. v.Cortex MCP, Inc.
· IPR2024-00487
Visa, Inc.'s IPR petition against Cortex MCP, Inc.'s patent was instituted by the PTAB, allowing the case to proceed to trial. The Board adopted key claim constructions, including defining 'OVER file' to encompass tokens and NFC interactions for 'scan,' confirming sufficient basis for unpatentability arguments.
patent all challenged claims upheld · Jan 25, 2024
Visa, Inc. v.Cortex MCP, Inc.
· IPR2024-00486
Visa's claims against Cortex MCP were upheld by the PTAB Director in a review of the Final Written Decision. The Board confirmed that Oborne discloses the token verification limitation central to Visa's patent.
patent final · Jan 25, 2024
TESLA, INC. v.iQar Inc.
· IPR2024-00499
The Board found all challenged claims unpatentable over combinations of Kudo-325 and Kudo-066. The petitioner successfully argued that the prior art combination teaches or suggests the necessary elements for destination prediction and power management in vehicles. This final decision affirms the obviousness rejection against iQar Inc.'s patent.
patent Final Written Decision · Jan 25, 2024
Visa, Inc. v.Cortex MCP, Inc.
· IPR2024-00486
The Board found that the majority of claims (24 out of 33) were unpatentable over various combinations of prior art references. The key finding was that Oborne teaches core tokenization elements, while other combinations failed to provide sufficient motivation for the claimed improvements.
patent · Jan 24, 2024
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
· IPR2024-00467
Dr. Reddy’s labs and Eye Therapies have jointly filed a motion to keep their settlement agreement confidential and separate from the IPR docket. The request cites statutory authority and seeks limited disclosure.
patent terminated or settled · Jan 24, 2024
Motorola Solutions, Inc. v.STA Group, LLC
· IPR2024-00207
Motorola Solutions and STA Group settled their dispute over Patent 8,145,249, filing a joint motion that led the PTAB to terminate the inter partes review.
patent · Jan 24, 2024
Motorola Solutions, Inc. v.STA Group, LLC
· IPR2024-00207
Motorola Solutions and STA Group filed a joint motion asking the PTAB to keep their settlement agreement confidential under 35 U.S.C. § 317(b). They contend the agreement contains highly sensitive business information that could be harmed if disclosed.
patent terminated or settled · Jan 24, 2024
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
· IPR2024-00467
Dr. Reddy’s Laboratories and Eye Therapies have settled their dispute over U.S. Patent No. 11,833,245 and jointly filed a motion to terminate the inter partes review. The Board is asked to end the proceeding under 35 U.S.C. § 317, citing policy and precedent favoring termination after settlement.
patent terminated or settled · Jan 24, 2024
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
· IPR2024-00467
Dr. Reddy’s Laboratories and Eye Therapies entered a settlement that led to the joint termination of two inter partes review proceedings covering patents 11,833,245 and 11,596,600. The Board granted the termination and kept the settlement agreement confidential.
